[64Cu]Cu-TE1PA-9E7.4

N/A

Report date: 2023/10/13 17:15:04

Base Information

Drug Name[64Cu]Cu-TE1PA-9E7.4
Drug Alias Name[64Cu]Cu-TE1PA-9E7.4
ClassificationRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionRadionuclide imaging enhancersAnti-CD138
TargetsSyndecan-1
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversité D'Angers (Angers, France)IMT AtlantiqueGIP Arronax
China Registration ClassN/A

Develop Information

Active CompaniesUniversité D'Angers (Angers, France)IMT AtlantiqueGIP Arronax
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A